Recent performance snapshot for Advanced Micro Devices (AMD) Advanced Micro Devices (AMD) has attracted fresh attention after a strong run in its shares, with the stock showing gains over the past week, month and past 3 months, drawing investors back to the semiconductor name. At a recent close of US$354.49 and a 1 day return of about 5%, AMD stands well above its past month and past 3 months perf...
Recent performance snapshot for Advanced Micro Devices (AMD) Advanced Micro Devices (AMD) has attracted fresh attention after a strong run in its shares, with the stock showing gains over the past week, month and past 3 months, drawing investors back to the semiconductor name. At a recent close of US$354.49 and a 1 day return of about 5%, AMD stands well above its past month and past 3 months performance. Its 1 year and multi year total returns sit at very large multiples of the starting...
Long-duration bond funds got brutalized when the 10-year Treasury yield spiked above 4.5% last year, and even high-yield credit funds gave back gains every time the VIX poked above 25. PIMCO 0-5 Year High Yield Corporate Bond Index ETF (NYSEARCA:HYS) was built for investors who want junk-bond income without that whipsaw. The fund tracks short-maturity ... This 7% Yielding ETF Keeps You Out Of Mark...
Long-duration bond funds got brutalized when the 10-year Treasury yield spiked above 4.5% last year, and even high-yield credit funds gave back gains every time the VIX poked above 25. PIMCO 0-5 Year High Yield Corporate Bond Index ETF (NYSEARCA:HYS) was built for investors who want junk-bond income without that whipsaw. The fund tracks short-maturity ... This 7% Yielding ETF Keeps You Out Of Market Volatility
It's official: SpaceX is aiming to go public sometime in 2026. I'm personally very excited about the impending SpaceX IPO . Some reports suggest that the space stock could go public as early as June. Those same reports claim that SpaceX will seek a $1.75 trillion valuation, hoping to raise up to $75 billion in fresh capital. If you're looking to invest in SpaceX , I have some exciting news: the co...
It's official: SpaceX is aiming to go public sometime in 2026. I'm personally very excited about the impending SpaceX IPO . Some reports suggest that the space stock could go public as early as June. Those same reports claim that SpaceX will seek a $1.75 trillion valuation, hoping to raise up to $75 billion in fresh capital. If you're looking to invest in SpaceX , I have some exciting news: the company apparently wants to make it very easy for smaller retail investors to participate. "Retail is going to be a critical part of this and a bigger part than any IPO in history," SpaceX CFO Bret Johnsen reportedly told a team of bankers in April. Apparently, Elon Musk wants to allocate up to 30% of shares for smaller investors, whereas most companies typically reserve just 5% to 10% for retail investors. Don't want to wait until this summer to invest? I have even more good news: the two investment vehicles below allow you to get exposure as early as today . Continue reading
Earnings Call Insights: Ardelyx (ARDX) Q1 2026 Management View “2026 is poised to be another significant year of growth for our company, and we're already off to a great start,” said (President, CEO & Director Michael Raab), adding that the company’s priorities are “accelerating the growth of IBSRELA, maintaining the XPHOZAH momentum, building and expanding our pipeline and delivering strong finan...
Earnings Call Insights: Ardelyx (ARDX) Q1 2026 Management View “2026 is poised to be another significant year of growth for our company, and we're already off to a great start,” said (President, CEO & Director Michael Raab), adding that the company’s priorities are “accelerating the growth of IBSRELA, maintaining the XPHOZAH momentum, building and expanding our pipeline and delivering strong financial results.” On IBSRELA, (CEO Michael Raab) said: “In the first quarter, our disciplined commercial execution drove 58% year-over-year revenue growth… and we remain on track to deliver at least $1 billion in annual revenue in 2029.” On pipeline expansion, (CEO Michael Raab) said: “Earlier this year, we initiated the ACCEL trial, a Phase III clinical trial evaluating IBSRELA for chronic idiopathic constipation… We remain on track to complete enrollment by year-end and to announce top line data in the second half of 2027.” Management also highlighted IP and leadership updates, with (CEO Michael Raab) citing “our recently announced Orange Book listed 2099 patent covering the commercial formulations of IBSRELA and XPHOZAH,” and stating: “I'm excited with the 2 newest additions who've joined the executive team, Felecia Ettenberg, our Chief Legal Officer; and Dr. Rajani Dinavahi, our Chief Medical Officer.” From the CFO on financial positioning and capital allocation, (Chief Financial Officer Sue Hohenleitner) said: “We are driving towards profitability and meaningful cash generation,” and added: “Importantly, we are funding current operations and pipeline from our revenue base, which demonstrates the growing financial maturity of Ardelyx.” Outlook (Chief Financial Officer Sue Hohenleitner) reiterated 2026 revenue guidance for IBSRELA and said: “We are reiterating our 2026 revenue guidance for IBSRELA between $410 million and $430 million.” For XPHOZAH, (CFO Hohenleitner) said: “We are reiterating our revenue guidance between $110 million and $120 million in 2026.” On the broad...
The UN’s climate science body is pressing ahead with its work despite the US government’s withdrawal from the Intergovernmental Panel on Climate Change (IPCC) earlier this year, the organisation’s top official has said. According to IPCC chair Jim Skea, around 110 to 120 of the UN body’s 195 members typically show up when it meets. “So the US has not been there. It’s one country, more or less,” Sk...
The UN’s climate science body is pressing ahead with its work despite the US government’s withdrawal from the Intergovernmental Panel on Climate Change (IPCC) earlier this year, the organisation’s top official has said. According to IPCC chair Jim Skea, around 110 to 120 of the UN body’s 195 members typically show up when it meets. “So the US has not been there. It’s one country, more or less,” Skea said on the sidelines of the Regional Ecological Summit in Kazakhstan last week. “The meetings...
BEIJING, China, May 01, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 34,085 vehicles in April 2026. As of April 30, 2026, Li Auto’s cumulative deliveries reached 1,669,442. In April, the all-new Li L9 Livis debuted at the 2026 Beijing International Automotive Exhibition,...
BEIJING, China, May 01, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 34,085 vehicles in April 2026. As of April 30, 2026, Li Auto’s cumulative deliveries reached 1,669,442. In April, the all-new Li L9 Livis debuted at the 2026 Beijing International Automotive Exhibition, with its official launch scheduled for May 15. The launch event will fully showcase the vehicle’s l
L3Harris' Missile Business Files To Go Public As Trump's War Economy Prepares For Launch We have been diligently tracking the Trump administration's war-economy mobilization across the homeland, from the rise of so-called " war unicorns " favored by the Department of War to Trump officials talking with GM, Ford, GE Aerospace, and Oshkosh about converting underused civilian industrial capacity into...
L3Harris' Missile Business Files To Go Public As Trump's War Economy Prepares For Launch We have been diligently tracking the Trump administration's war-economy mobilization across the homeland, from the rise of so-called " war unicorns " favored by the Department of War to Trump officials talking with GM, Ford, GE Aerospace, and Oshkosh about converting underused civilian industrial capacity into weapons production. The signal to investors is becoming hard to miss: the Trump administration is preparing to expand the defense industrial base at scale to refill depleted weapons stockpiles. Whether through venture-backed defense startups, legacy defense primes, or redirected auto and heavy-manufacturing capacity, the White House's war policies point toward a major weapons-production boom on the horizon. With that in mind, L3Harris Technologies has confidentially filed a draft S-1 with the SEC for a proposed IPO of its Missile Solutions business, or MSL. L3Harris is now preparing for an IPO, as the SEC privately reviews the draft registration statement and may send comments or request changes. This occurs before the IPO roadshow begins. Last week, L3Harris announced it had closed a $1 billion investment from the DoW into MSL, which will be used to "accelerate research and development, and increase production capacity for critical national security technologies." "This strategic partnership with the Department of War is a testament to the critical role L3Harris plays in our national security," L3Harris CEO Christopher Kubasik wrote in a statement. Kubasik noted, “The investment will allow us to accelerate innovation and enhance our ability to deliver the advanced capabilities our warfighters need to deter and defeat emerging threats. We are proud to partner with the DoW to ensure the resilience of our defense industrial base for years to come." Related: Race To Refill U.S. Weapons Stockpiles Will Supercharge War Economy War Economy Returns: From Trucks To Tanks, Pentagon...
Seaport Therapeutics Inc. , a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range. The neuro-psychiatry company sold 14.16 million shares at $18 each, according to a statement Thursday confirming an earlier Bloomberg News report. The biotech firm had offer...
Seaport Therapeutics Inc. , a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range. The neuro-psychiatry company sold 14.16 million shares at $18 each, according to a statement Thursday confirming an earlier Bloomberg News report. The biotech firm had offered 11.8 million shares for $16 to $18 each, its filings show. At the IPO price, the Boston-based firm has a market value of about $912 million based on the outstanding shares listed in the filings. The listing was significantly oversubscribed, people familiar with the matter said earlier. Biotechnology IPOs have picked up in recent weeks. The latest, blood coagulation disorder drugmaker Hemab Therapeutics Holdings Inc., raised $301.5 million in an upsized US initial public offering that priced earlier Thursday. Founded in 2024, the clinical-stage company is developing therapies to treat patients with major depressive disorder and generalized anxiety disorder. The company, which is backed by PureTech Health Plc , had a net loss of $74.9 million last year, compared with a net loss of $46.9 million a year earlier, according to the filings. Nasdaq and London Stock Exchange-listed PureTech’s stake is expected to decline to 33% after the offering from 43%, the filings show. Affiliates of Arch Ventures Partners will have a 10% stake, down from 13%, and General Atlantic is set to have 6.6%, down from 8.6%. For the latest news on equity capital markets activity in the US, Canada and Latin America, follow the channel or visit NI BFWECMUS . To subscribe to ECM Watch , Bloomberg’s daily roundup of news from around the region, click here . The offering is being led by Goldman Sachs Group Inc. , JPMorgan Chase & Co. , Leerink Partners , Citigroup Inc. and Stifel Financial Corp. The shares are expected to trade on the Nasdaq Global Market under the symbol SPTX.
Beijing urges Washington to ‘make the right choices’ on Taiwan to maintain ‘stability’ between the two powers China’s foreign minister on Thursday urged the US to maintain “stability” between the two powers and warned that Taiwan posed the biggest risk, weeks ahead of President Donald Trump’s scheduled visit to Beijing. In a call with the US secretary of state, Marco Rubio, foreign minister Wang Y...
Beijing urges Washington to ‘make the right choices’ on Taiwan to maintain ‘stability’ between the two powers China’s foreign minister on Thursday urged the US to maintain “stability” between the two powers and warned that Taiwan posed the biggest risk, weeks ahead of President Donald Trump’s scheduled visit to Beijing. In a call with the US secretary of state, Marco Rubio, foreign minister Wang Yi said that Beijing and Washington should “safeguard the hard-won stability” in China-US relations, China’s foreign ministry said. Continue reading...
marekuliasz/iStock Editorial via Getty Images I first covered Amprius Technologies, Inc. ( AMPX ), back in February. I liked the growth potential of the company and the market in which it operates. Battery technology demand is only growing. One of the things I liked is that their battery technology is utilized in some fast-growing markets, such as UAVs, and not just the car space. Their market opp...
marekuliasz/iStock Editorial via Getty Images I first covered Amprius Technologies, Inc. ( AMPX ), back in February. I liked the growth potential of the company and the market in which it operates. Battery technology demand is only growing. One of the things I liked is that their battery technology is utilized in some fast-growing markets, such as UAVs, and not just the car space. Their market opportunity is continuing to grow with eVTOLs, robotics, space, and other markets. The valuation was a little rich for me at the time of writing . I rated the stock a hold and would look for any pullbacks to enter a long position. At the time I covered the stock, it was trading in the mid-$11 a share; when it pulled back below $10 a share, I took a position in the stock. My only regret was not taking a larger position. Amprius has been on a tear to start the year. The company has seen its stock price increase by over 160% year to date. The company reported strong quarterly results, particularly on the margin side of the business. Current world events have also helped drive the stock. There is increased demand on the military side for drones. Also, many are seeing the reliance on oil and seeing alternative energy options as a solution. Amprius is well positioned to capitalize on growing demand. Seeking Alpha The company has seen strong growth as its products have fully entered the market. The performance of its products continues to drive demand in the market. Its new battery, SiCore, is fully implemented in the market and is much more profitable as well. The company has crossed over into the point of profitability as well, which is a big step for a small, growing company. This should help drive value for the company going forward. Similar to last time I reviewed the stock, I like the company and the industry in which it operates. I think the recent run-up has positioned the stock at a high valuation. Financials The company has seen strong growth as it has entered the full comm...